S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
PROOF: New One Ticker (Weekly) Payouts (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Laser breakthrough could send stock soaring 2,467% (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
PROOF: New One Ticker (Weekly) Payouts (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Laser breakthrough could send stock soaring 2,467% (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
PROOF: New One Ticker (Weekly) Payouts (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Laser breakthrough could send stock soaring 2,467% (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
PROOF: New One Ticker (Weekly) Payouts (Ad)
Consumers are increasingly pushing back against price increases — and winning
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
AI Stock Caught Trading Under Secret Name (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Laser breakthrough could send stock soaring 2,467% (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes

CytoMed Therapeutics (GDTC) Stock Forecast & Price Target

$2.20
-0.03 (-1.35%)
(As of 02/23/2024 ET)

CytoMed Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$5.00
127.27% Upside
High Forecast$5.00
Average Forecast$5.00
Low Forecast$5.00
TypeCurrent Forecast
2/25/23 to 2/25/24
1 Month Ago
1/26/23 to 1/26/24
3 Months Ago
11/27/22 to 11/27/23
1 Year Ago
2/25/22 to 2/25/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$5.00$5.00$5.00N/A
Predicted Upside127.27% Upside42.05% Upside29.87% UpsideN/A
Get CytoMed Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.

GDTC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GDTC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CytoMed Therapeutics Stock vs. The Competition

TypeCytoMed TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside127.27% Upside1,899.82% Upside7.54% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/4/2023Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00+42.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:39 PM ET.












GDTC Price Target - Frequently Asked Questions

What is CytoMed Therapeutics's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for CytoMed Therapeutics stock is Buy based on the current 1 buy rating for GDTC. The average twelve-month price prediction for CytoMed Therapeutics is $5.00 with a high price target of $5.00 and a low price target of $5.00. Learn more on GDTC's analyst rating history.

Do Wall Street analysts like CytoMed Therapeutics more than its competitors?

Analysts like CytoMed Therapeutics more than other Medical companies. The consensus rating for CytoMed Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how GDTC compares to other companies.

Does CytoMed Therapeutics's stock price have much upside?

According to analysts, CytoMed Therapeutics's stock has a predicted upside of 42.05% based on their 12-month stock forecasts.

What analysts cover CytoMed Therapeutics?

CytoMed Therapeutics has been rated by Benchmark in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GDTC) was last updated on 2/25/2024 by MarketBeat.com Staff

From Our Partners